Association of Major Depressive Disorder with remotely administered measures of cognition and subjective report of cognitive difficulties across the adult age spectrum.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 04 2023
Historique:
received: 25 07 2022
revised: 04 11 2022
accepted: 11 12 2022
pubmed: 18 12 2022
medline: 25 2 2023
entrez: 17 12 2022
Statut: ppublish

Résumé

Major depressive disorder (MDD) has increasing prevalence with age. Both objective measures of cognitive dysfunction and subjective report of cognitive difficulties related to MDD are often thought to worsen with increasing age. However, few studies have directly evaluated these characteristics across the adult lifespan. Participants included 23,594 adults completing objective and subjective measures of cognition on an online research registry. Linear regression including interactions of age group with depression was used to evaluate the association of self-reported MDD with measures of cognition in three age groups: 21-40 years; 41-60 years; 61+ years. MDD (n = 2127) demonstrated poorer objective cognitive performance and greater subjective ratings of cognitive difficulties across all domains assessed compared to non-depressed individuals (ND; n = 21,467). Significant interactions of age group and MDD status with objective and subjective measures of cognition were observed for both middle age and older adults when compared to young adults but few significant differences between middle-aged and older adults were evident. This study relied on self-report of MDD diagnosis, utilized remotely administered and unsupervised measures of cognition, and the sample was not diverse. The magnitude of association between MDD and cognitive correlates appears to plateau in middle age. Our results suggest that increased rates of dementia are not due to greater cognitive consequence of MDD in older adults and that age effects, and not greater effects of depression, may lead to increased diagnosis of MDD based on subjective report of cognitive symptoms.

Sections du résumé

BACKGROUND
Major depressive disorder (MDD) has increasing prevalence with age. Both objective measures of cognitive dysfunction and subjective report of cognitive difficulties related to MDD are often thought to worsen with increasing age. However, few studies have directly evaluated these characteristics across the adult lifespan.
METHODS
Participants included 23,594 adults completing objective and subjective measures of cognition on an online research registry. Linear regression including interactions of age group with depression was used to evaluate the association of self-reported MDD with measures of cognition in three age groups: 21-40 years; 41-60 years; 61+ years.
RESULTS
MDD (n = 2127) demonstrated poorer objective cognitive performance and greater subjective ratings of cognitive difficulties across all domains assessed compared to non-depressed individuals (ND; n = 21,467). Significant interactions of age group and MDD status with objective and subjective measures of cognition were observed for both middle age and older adults when compared to young adults but few significant differences between middle-aged and older adults were evident.
LIMITATIONS
This study relied on self-report of MDD diagnosis, utilized remotely administered and unsupervised measures of cognition, and the sample was not diverse.
CONCLUSIONS
The magnitude of association between MDD and cognitive correlates appears to plateau in middle age. Our results suggest that increased rates of dementia are not due to greater cognitive consequence of MDD in older adults and that age effects, and not greater effects of depression, may lead to increased diagnosis of MDD based on subjective report of cognitive symptoms.

Identifiants

pubmed: 36528135
pii: S0165-0327(22)01405-7
doi: 10.1016/j.jad.2022.12.045
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-205

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Conflict of interest During the past three years, Dr. Mackin has received research support from The National Institute of Mental Health and Janssen Research and Development, LLC. Dr. Weiner has served on the Scientific Advisory Boards for Pfizer, BOLT International, Neurotrope Bioscience, Alzheon, Inc., Alzheimer's Therapeutic Research Institute (ATRI), Eli Lilly, U. of Penn's Neuroscience of Behavior Initiative, National Brain Research Centre (NBRC), India, Dolby Family Ventures, LP, and ADNI. Dr. Neuhaus has received research support from The National Institute on Aging. Dr. Nosheny has received research support from The National Institute on Aging; the California Department of Public Health; Genentech, Inc.; and the Alzheimer's Association. Dr. Ashford has received research support from the National Institute of Aging. Drs. Rhodes, Kassel, Knight, Banh, Ashford, and Tank, and Emily Burns, Monica R. Camacho, Diana Truran, Chengshi Jin, and Joseph Eichenbaum reported no biomedical financial interests or potential conflicts of interest.

Auteurs

R Scott Mackin (RS)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA; Mental Illness Research Education and Clinical Centers, Veterans Affairs Medical Center, San Francisco, CA, USA. Electronic address: Scott.mackin@ucsf.edu.

Chengshi Jin (C)

Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.

Emily Burns (E)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA.

Michelle Kassel (M)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA; Mental Illness Research Education and Clinical Centers, Veterans Affairs Medical Center, San Francisco, CA, USA.

Emma Rhodes (E)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA; Mental Illness Research Education and Clinical Centers, Veterans Affairs Medical Center, San Francisco, CA, USA.

Rachel Nosheny (R)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Miriam Ashford (M)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Tim Banh (T)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Joseph Eichenbaum (J)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Kristen Knight (K)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Rachana Tank (R)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Monica R Camacho (MR)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Juliet Fockler (J)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

Diana Truran (D)

VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA.

John Neuhaus (J)

Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.

Michael Weiner (M)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH